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Centres participating in Arterial Revascularisation Trial (ART). Principal 
Investigators in bold, co-investigators (number of patients enrolled).   
 
1. John Radcliffe Hospital, Oxford, UK. D Taggart, Ratnatunga, S Westaby, J 
Cook, C Wallis (427) 
2. Medical University of Silesia (2nd Department of Cardiac Surgery), Katowice, 
Poland. S Wos, M Jasinski, K Widenka, A Blach, R Gocol, D Hudziak, P 
Zurek, M Deja, R Bachowski, R Mrozek, T Kargul, W Domarardzki, J 
Frackiewicz (256)  
3. Edinburgh Royal Infirmary, Edinburgh, UK. V Zamvar, D Ezakadan (217) 
4. Austin and Repatriation Medical Centre, Melbourne, Australia. B Buxton, S 
Seevanayagam, G Matalanis, A Rosalion, J Negri, S Moten, V Atkinson, A 
Newcomb, P Polidano, R Pana, S Gerbo (192) 
5. University Hospital of Wales, Cardiff, UK, P O’Keefe, U von Oppell, D 
Mehta, A Azzu, A Szafranek, E Kulatilake, J Evans, N Martin, D Banner 
(185) 
6. Royal Sussex County, Brighton, UK. U Trivedi, A Forsyth, J Hyde, A 
Cohen, M Lewis, E Gardner, A MacKenzie, N Cooter, E Joyce, J Parker, F 
Champney (180) 
7. Freeman Hospital, Newcastle, UK. S Clark, J Dark, K Tocewicz, T Pillay, S 
Rowling, J Adams-Hall (152) 
8. Medical University of Silesia (1st Department of Cardiac Surgery), Katowice, 
Poland. A Bochenek, M Cisowski, M Bolkowski, W Morawski, M Guc, M 
Krejca , M Wilczynski, A Duralek, W Gerber, J Skarysz, R Shrestha, W 
Swiech, P Szmagala, L Krzych, A Pawlak, K Kepa (145) 
9. Royal Infirmary, Manchester, UK. R Hasan, D Keenan, B Prendergast, N 
Odom, K McLaughlin, G Cummings-Fosong, C Mathew, H Iles-Smith, A 
Oomen (115) 
10. King's College Hospital, London, UK. J Desai, A El-Gamel, L John, O 
Wendler, M Andrews, K Rance, R Williams,  V Hogervorst, J Gregory, J 
Jessup, A Knighton, A Hoare (114) 
11. Papworth Hospital, Cambridge, UK.  A Ritchie, C Choong, S Nair, D 
Jenkins, S Large, C Sudarshan, M Barman, K Dhital, T Routledge, B 
Rosengard, H Munday, K Rintoul, E Jarrett, S Lao-Sirieix, A Wilkinson, L 
Garner, J Osmond, H Holcombe (101) 
12. Castle Hill Hospital, Hull, UK. A Cale, S Griffin, J Dickson, J Cook (97) 
13. Glenfield Hospital, Leicester, UK. T Spyt, M Hickey, A Sosnowski, G Peek, J 
Szostek, L Hadjinikalaou, E Logtens, M Oakley, S Leji (95) 
14. Harefield Hospital, London, UK. J Gaer, M Amrani, G Dreyfus, T Bahrami, 
F de Robertis, K Baig, G Asimakopoulos,H Vohra, V Pai, S Tadjkarimi, 
Soleimani, G Stavri, G Bull, H Collappen (94) 
15. John Paul II, Krakow, Poland. J Sadowksi, B Gaweda, P Rudzinski, J 
Stolinski, J Konstanty-Kalandyk (92) 
16. Heart Institute of Pernambuco, Recife, Brazil. F Moraes, C Moraes, J 
Wanderley (82) 
17. Royal Brompton Hospital, London, UK. J Pepper, A De Souza, M Petrou, R 
Trimlett, T Morgan, J Gavino, SF Wang (82) 
18. St George’s Hospital, London, UK. V Chandrasekaran, R Kanagasaby, M 
Sarsam, H Ryan, L Billings, L Ruddick, A Achampong, E Forster (78) 
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19. Medical University of Gdansk, Gdansk, Poland. R Pawlaczyk, P Siondalski, J 
Rogowski, K Roszak, K Jarmoszewicz, D Jagielak, S Gafka (74) 
20. Care Hospital, Hyderabad, India. G Mannam, Naguboyin, L Rao Sajja, B 
Dandu (69) 
21. Northern General Hospital, Sheffield, UK. N Briffa, P Braidley, G Cooper, A 
Knighton, K Allen, G Sangha, C Bridge, H McMellon (67) 
22. Ospedale Mauriziano, Turin, Italy. R Casabona, G Actis Dato, G Bardi, S 
Del Ponte, Forsennati, F Parisi, G Punta, R Flocco, F Sansone, E Zingarelli 
(60) 
23. The Cardiothoracic Centre, Liverpool, UK. W Dihmis, M Kuduvali, C 
Prince, H Rogers, L McQuade (50) 
24. Szpital Uniwersytecki, Bydgoszcz, Poland. L Anisimowicz, M Bokszanski, W 
Pawliszak, J Kolakowski, G Lau, W Ogorzeja, I Gumanska, P Kulinski (23) 
25. Landesklinikum, St Polten, Austria. B Podesser, K Trescher, O Bernecker, Ch 
Holzinger, K Binder, I Schor, P Bergmann, H Kassal, B Motovova (20) 
26. Escorts Heart Institute, New Delhi, India. N Trehan, Z Meharwal, R 
Malhotra, M Goel, B Kumer, S Bazaz, N Bake, A Singh, Y Mishka, R Gupta, 
S Basumatary (19) 
27. Silesian Centre for Heart Disease, Zabrze, Poland. M Zembala, B Szafron, J 
Pacholewicz, M Krason, Farmas, Wojarski, Zych (10) 
28. Szpital Wojewodzki 2, Rzeszow, Poland. K Widenka, I Szymanik, M 
Kolwca, W Mazur, A Kurowicki, S Zurek, T Stacel, I Jaworska (6) 
 
Trial Steering Committee 
1. Professor P Sleight, Emeritus Professor Cardiovascular Medicine, Oxford, UK 
(Chairman) 
2. Professor D Altman, Professor of Statistics in Medicine, Oxford, UK 
3. Professor K Channon, Professor of Cardiovascular Medicine, Oxford, UK 
4. Professor J Dark, Professor of Cardiac Surgery, Newcastle, UK 
5. Ms B Farrell, Trials Director, National Perinatal Epidemiology Unit, Oxford, 
UK 
6. Dr M Flather, Professor of Medicine and Clinical Trials, Norwich, UK 
7. Professor A Gray, Professor of Health Economics, Oxford, UK 
8. Professor J Pepper, Professor of Cardiac Surgery, London, UK 
9. Dr R Stables, Consultant Cardiologist, Liverpool, UK 
10. Professor D Taggart Consultant Cardiac Surgeon, Oxford, UK (Chief 
Investigator) 
11. The late Professor G Vermes, Emeritus Professor of Hebrew Studies, Oxford, 
UK (Patient Lay Member) 
12. Professor J Pearson British Heart Foundation, London, UK (Observer) 
13. Dr M Pitman, Medical Research Council, London, UK (Observer) 
14. Dr Belinda Lees, Trials Coordinator, Oxford UK (Observer) 
 
Data Monitoring Committee  
1. Professor S Yusuf, Professor of Medicine, Hamilton, Canada (Chairman) 
2. Professor S Pocock, Professor of Medical Statistics, London, UK 
3. Professor D Julian, Emeritus Professor of Cardiology, London, UK 
4. Professor T Treasure, Professor of Cardiothoracic Surgery, London, UK 
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Clinical Event Adjudicators 
1. Mr U Trivedi, Royal Sussex County Hospital, Brighton, UK 
2. Mr P O'Keefe, University Hospital of Wales, Cardiff, UK 
3. Professor U Von Oppel, University Hospital of Wales, Cardiff, UK 
4. Mr V Zamvar, Edinburgh Royal Infirmary, Edinburgh, UK 
5. Mr A Cale, Castle Hill Hospital, Hull, UK 
6. Mr M Hickey, Glenfield Hospital, Leicester, UK 
7. Mr T Spyt, Glenfield Hospital, Leicester, UK 
8. Professor J Pepper, Royal Brompton Hospital, London, UK  
9. Mr R Kanagasabay, St. George's Hospital, London, UK  
10. Mr T Pillay, Freeman Hospital, Newcastle, UK 
11. Mr P Braidley, Northern General Hospital, Sheffield, UK 
12. Mr G Cooper, Northern General Hospital, Sheffield, UK 
13. Prof M Flather, University of East Anglia, Norwich, UK  
14. Dr J Collinson, Chelsea and Westminster Hospital, London, UK  
15. Dr A Bakhai, Barnet General Hospital, Barnet, UK 
16. Dr R Pawlaczyk, Medical University Of Gdansk, Gdansk, Poland 
17. Dr R O'Hanlon, Royal Brompton Hospital, London, UK  
18. Dr D Kotecha, University of Birmingham, Birmingham UK 
19. Dr K Qureshi, London Chest Hospital, London, UK 
20. Dr L Krzych, Medical University Of Silesia, Katowice, Poland 
21. Dr T Geisler, University Hospital Tuebingen, Tuebingen, Germany 
22. Mr N Briffa, Northern General Hospital, Sheffield, UK 
23. Dr L Manzano-Espinosa, Hospital Universitario Ramón y Cajal Madrid, Spain 
24. Dr M Jasinski, Medical University Of Silesia, Katowice, Poland 
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Definitions of Serious Adverse Events used in ART 
 
1. Death 
 
(a) Death due to cardiac causes: 
Cardiac causes of death such as congestive heart failure, arrhythmia or myocardial 
infarction. 
(b) Other vascular causes of death: 
Vascular causes of death such as pulmonary embolus, dissection, cerebrovascular 
accident or bleeding event. 
(c) Non-cardiovascular causes of death: 
This includes any other cause of death 
 
2. Major Bleed 
 
A major bleeding event is defined as requiring the use of blood products or a surgical 
procedure to deal with the bleed or its sequelae. 
 
3. Cerebrovascular Accident (CVA) 
 
A CVA is defined as a new focal neurological deficit thought to be vascular in origin 
with signs and symptoms lasting more than 24 hours. 
 
4. Revascularization 
 
For the purpose of the trial a revascularization is described as a Coronary Artery 
Bypass Graft (CABG) or Percutaneous Coronary Intervention (PCI) after the trial 
procedure. 
 
5. Myocardial Infarction (MI) 
 
(a) Non peri-procedural MI 
MI definition (2 out of the following 3 criteria must be present) 
 New onset or worsening pattern of characteristic ischemic chest pain occurring 
at rest or with minimal exercise lasting longer than 20 minutes and requiring 
nitrates or narcotic analgesia for relief of pain. 
 Elevation of cardiac markers (CK, CK-MB or Troponin) to at least twice the 
upper limit of the normal reference range (or greater than 20% of the previous 
value if already elevated in the context of early hospital MI).  
 ECG changes compatible with ischemia 
 
(b) MI within 48 hours of PTCA 
MI post-PTCA defined as: 
 the standard as above (at least 2 of 3 criteria)  
or  
 elevation of cardiac markers to at least 3 x the upper limit of normal  
 
(c) MI within 72 hours of CABG 
MI post-CABG defined as: 
 elevation of cardiac markers to at least 5 x the upper limit of normal  
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or 
 development of new pathological Q waves in at least two contiguous leads.  
 
Other Serious Adverse Events 
 
A “Serious Adverse Event” is defined as requiring or prolonging hospital admission 
for medical reasons.  The hospitalization does not have to be related to the study 
procedure or patient’s underlying cardiovascular disease for it to constitute an “Other 
SAE”.    
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Supplementary Appendix Table S1 
Details of surgical procedure, post-operative care and hospital stay 
 
Procedures Single graft group Bilateral graft group 
Details of operation  (n=1546) (n=1531) 
On pump 928 (60.0%) 890 (58.1%) 
Off pump  618 (40.0%) 641 (41.9%) 
Intra-operative 
conversions to bypass  
13/618 (2.1%) 15/641 (2.3%) 
Mean (SD) duration of 
operation, mins 
Median (IQR) 
199 (58) 
 
190 (160 to 250) 
222 (61) 
 
215 (185 to 250) 
Number of vessels grafted  (n=1546) (n=1530) 
1 11 (0.7%) 8 (0.5%) 
2 273 (17.7%) 272 (17.8%) 
3 749 (48.54%) 771 (50.4%) 
4+ 513 (33.2%) 479 (31.3%) 
Blood products used 
during surgery 
  
Aprotinin started during 
surgery 
372/1545 (24.1%) 368/1531 (24.0%) 
Aprotinin given after surgery 89/1545 (5.8%) 98/1530 (6.4%) 
Blood transfusion 184/1515 (12.2%) 179/1492 (12.0%) 
Median (IQR) blood (red 
cells)  
500 (300 to 600)) 500 (300 to600) 
Platelets 35/1512 (2.3%) 46/1494 (3.1%) 
Fresh Frozen Plasma (FFP) 53/1513 (3.5%) 66/1493 (4.4%) 
Cell saver 474/1500 (31.6%) 461/1479 (31.2%) 
Immediate post-operative 
period  
  
Return to theatre and reason 54/1546 (3.5%) 66/1532 (4.3%) 
Bleeding 44 51 
Tamponade 2 6 
Other 8    9 
Unknown 3 6 
Intra-aortic balloon pump 
used (IABP) 
57/1546 (3.7%) 68/1532 (4.4%) 
Renal support therapy 68/1545 (4.4%) 91/1532 (5.9%) 
 (n=1539) (n=1524) 
Mean (SD) Duration of 
ventilation (minutes) 
Median (IQR) 
863 (3293) 
 
580 (335-830) 
968 (3029) 
 
598 (360 to 890) 
Pre-discharge details (n=1447) (n=1429) 
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ITU admissions: 0 8 (0.6%) 8 (0.6%) 
1 1390 (96.1%) 1362 (95.3%) 
2 or more 49 (3.4%) 59 (4.1%) 
 (n=1551) (n=1538) 
Mean (SD) ITU length of 
stay (hours) 
Median (IQR) 
38 (106) 
 
22 (16 to 43) 
41 (94) 
 
22 (15 to 45) 
Mean (SD) HDU length of 
stay (days) 
Median (IQR) 
2 (3.7) 
 
1 (1 to 2) 
2 (3.8) 
 
1 (1 to 2) 
Mean (SD) post-operative 
total hospital stay (days) 
Median (IQR) 
7.5 (7.6) 
 
6 (5 to 8) 
8.0 (7.4) 
 
6.5 (5 to 8) 
ITU = intensive therapy unit; HDU = high dependency unit, IQR = interquartile range 
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Supplementary Appendix Table S2 
Medications at 5 years 
Medication [n (%)] 
Single graft group 
(n=1176) 
Bilateral graft group 
(n=1179) 
Aspirin 89.2% 88.6% 
Clopidogrel 10.7% 9.1% 
Warfarin 5.5% 5.2% 
Other anticoagulant 0.9% 1.2% 
Beta-blockers 78.3% 74.1% 
Calcium-channel antagonist 17.3% 18.7% 
Nitrates 7.5% 8.4% 
Potassium channel activators 2.9% 3.2% 
Statins 90.1% 88.0% 
Other lipid lowering agent 5.1% 5.8% 
ACE inhibitor 57.4% 58.1% 
Angiotensin-II receptor blocker 15.3% 15.9% 
Diuretics  20.2% 19.1% 
Digoxin 2.2% 1.0% 
Amiodarone 1.0% 1.3% 
*Medication information is provided for those with complete case report form data at 
5 years.  There are no significant differences in treatment frequencies between the two 
groups except Digoxin p<0.05 
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Supplementary Appendix Table S3 
Classification of causes of death  
Cause of death Single graft 
group  
(n=1554) 
Bilateral graft 
group 
(n=1548) 
Subdistribution 
Hazard Ratio 
(95% CI) 
P value 
Cardiac 42 (2.7%) 42 (2.7%) 1.00 (0.65, 1.54) 0.98 
Non CV 64 (4.1%) 67 (4.3%) 1.05 (0.75, 1.49) 0.76 
Other vascular 13 (0.8%) 13 (0.8%) 1.01 (0.47, 2.17) 0.99 
Unable to classify 11 (0.7%) 12 (0.8%) 1.10 (0.49, 2.49) 0.82 
Hazard ratios use the single graft group as the control 
 
 
Supplementary Appendix Table S4 
Per protocol (comparison based on patients who actually received assigned 
treatment) and “as-treated” (based on the actual operation carried out) analyses 
Outcome Single 
graft 
group  
N 
Bilateral 
graft 
group 
N 
Deaths 
Single graft 
group  
Deaths 
Bilateral 
graft group 
Hazard 
Ratio 
(95% CI) 
P 
value 
Primary – ITT 
unadjusted 
1554 1548 
130 (8.4%) 134 (8.7%) 
1.04  
(0.81, 1.32) 
0.77 
ITT – adjusted 
1554 1548 
130 (8.4%) 134 (8.7%) 
1.03 (0.81, 
1.32) 
0.80 
Per protocol – 
unadjusted 
1494 1294 
125 (8.4%) 105 (8.1%) 
0.97  
(0.75, 1.25) 
0.81 
Per protocol – 
adjusted* 
1494 1294 
125 (8.4%) 105 (8.1%) 
1.01  
(0.78, 1.31) 
0.95 
As-treated – 
unadjusted 
1709 1332 
149 (8.7%) 107 (8.0%) 
0.92  
(0.72, 1.18) 
0.50 
As-treated – 
adjusted* 
1709 1332 
149 (8.7%) 107 (8.0%) 
0.98  
(0.76, 1.26) 
0.87 
* Adjusted for age, gender, diabetes and ejection fraction 
Hazard ratios use the single graft group as the control 
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Supplementary Table S5. Health related quality of life assessed at 5 years 
Measure Single graft 
group  
N=1124§ 
Bilateral graft 
group  
N=1128§ 
P value 
Shortened WHO Rose Angina 
Questionnaire: 
   
Do you ever have any pain or 
discomfort in your chest? 
   
Yes (%) 317 (28.9%) 353 (32.1%)  
No (%) 780 (71.1%) 748 (67.9%) 0.11 
Missing 27 17  
When you walk at an ordinary pace 
on the level does this produce the 
pain?* 
   
Yes (%) 74 (23.9%) 83 (24.3%)  
No (%) 230 (74.2%) 256 (74.9%) 0.51 
Unable (%) 6 (1.9%) 3 (0.8%)  
Missing 7 11  
When you walk uphill or hurry does 
this produce the pain?* 
   
Yes (%) 192 (62.3%) 221 (65.0%)  
No (%) 104 (33.8%) 104 (30.6%) 0.67 
Unable (%) 12 (3.9%) 15 (4.4%)  
Missing 9 13  
EQ-5D      
Mean (SD) index score 
(1=full health, 0=dead) 
0.811 (0.251) 0.819 (0.237) 
0.47 
SF-36 **, Mean (SD) 
  
 
Physical functioning 72 (28) 71 (28)  
Role-physical 72 (30) 72 (30)  
Bodily Pain 81 (22) 81 (22.5)  
General Health 63 (23) 62 (23)  
Vitality 60 (22) 58 (23)  
Social Functioning 81 (27) 81 (26)  
Role - Emotional 82 (27) 81 (26)  
Mental Health 77 (18) 77 (18)  
§ All analyses based on numbers of patients providing data; no imputation was 
performed for missing data. Numbers available for analysis vary slightly for SF-36 
domains * Responses reported only for patients answering Yes to question 1 on the 
Shortened WHO Rose Angina Questionnaire (WHO = World Health Organisation) 
** No significant differences in SF-36 scores 
